Analysts Set Expectations for Upstream Bio Q4 Earnings

Upstream Bio, Inc. (NASDAQ:UPB) – Equities research analysts at William Blair issued their Q4 2025 earnings per share estimates for Upstream Bio in a research note issued on Thursday, November 7th. William Blair analyst M. Phipps forecasts that the company will post earnings per share of ($0.66) for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Upstream Bio’s current full-year earnings is ($5.75) per share.

Other equities analysts also recently issued research reports about the company. TD Cowen began coverage on Upstream Bio in a research report on Tuesday, November 5th. They issued a “buy” rating on the stock. JPMorgan Chase & Co. started coverage on Upstream Bio in a research report on Tuesday, November 5th. They issued an “overweight” rating and a $38.00 target price on the stock. Finally, Piper Sandler started coverage on Upstream Bio in a research report on Tuesday, November 5th. They set an “overweight” rating and a $75.00 price objective on the stock.

Upstream Bio Stock Performance

NASDAQ UPB opened at $26.80 on Monday. Upstream Bio has a 1-year low of $20.74 and a 1-year high of $29.46.

Insider Buying and Selling

In other Upstream Bio news, Director Erez Chimovits bought 825,000 shares of the business’s stock in a transaction on Tuesday, October 15th. The stock was bought at an average price of $17.00 per share, with a total value of $14,025,000.00. Following the completion of the purchase, the director now directly owns 4,554,873 shares in the company, valued at $77,432,841. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Upstream Bio news, major shareholder Ai Upstream Llc bought 1,175,000 shares of the business’s stock in a transaction on Tuesday, October 15th. The stock was bought at an average price of $17.00 per share, with a total value of $19,975,000.00. Following the completion of the purchase, the insider now directly owns 1,175,000 shares in the company, valued at $19,975,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Erez Chimovits acquired 825,000 shares of the company’s stock in a transaction dated Tuesday, October 15th. The stock was purchased at an average cost of $17.00 per share, with a total value of $14,025,000.00. Following the completion of the purchase, the director now directly owns 4,554,873 shares of the company’s stock, valued at approximately $77,432,841. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.